HELIX DIAGNOSTICS
Pharmacogenomics (PGx) Proton Pump Inhibitors CYP2C19 Panel
Panel Description
Proton pump inhibitors are prescribed to patients with gastroesophageal reflux disease (GERD), peptic ulcer disease and other conditions related to dysfunctional gastric acid secretion. Certain CYP2C19 metabolizer types may reduce efficacy of PPIs, while others may lead to increased risk for adverse events.
Patients for whom omeprazole, lansoprazole, pantoprazole, and dexlansoprazole are being considered, have been ineffective or caused side effects.
Genes Tested (1)
Important Panel Information
Turnaround time: 7-10 days
Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
GERD, stomach or duodenal ulcers, H. pylori infection, or other conditions causing stomach acid irritation.
All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.